Adicet Market Capitalization from 2010 to 2024
ACET Stock | USD 0.90 0.01 1.10% |
Check Adicet Bio financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adicet Bio's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.2 M, Interest Expense of 23.8 K or Selling General Administrative of 34.7 M, as well as many indicators such as Price To Sales Ratio of 12.57, Dividend Yield of 0.0 or PTB Ratio of 0.45. Adicet financial statements analysis is a perfect complement when working with Adicet Bio Valuation or Volatility modules.
Adicet | Market Capitalization |
Latest Adicet Bio's Market Capitalization Growth Pattern
Below is the plot of the Market Cap of Adicet Bio over the last few years. It is Adicet Bio's Market Cap historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adicet Bio's overall financial position and show how it may be relating to other accounts over time.
View | Last Reported 75.31 M | 10 Years Trend |
|
Market Cap |
Timeline |
Adicet Market Capitalization Regression Statistics
Arithmetic Mean | 478,363,161 | |
Geometric Mean | 311,795,436 | |
Coefficient Of Variation | 114.82 | |
Mean Deviation | 360,309,117 | |
Median | 318,606,104 | |
Standard Deviation | 549,249,285 | |
Sample Variance | 301674.8T | |
Range | 1.7B | |
R-Value | (0.04) | |
Mean Square Error | 324355.8T | |
R-Squared | 0 | |
Significance | 0.89 | |
Slope | (4,935,609) | |
Total Sum of Squares | 4223446.9T |
Adicet Market Capitalization History
About Adicet Bio Financial Statements
Adicet Bio shareholders use historical fundamental indicators, such as Market Capitalization, to determine how well the company is positioned to perform in the future. Although Adicet Bio investors may analyze each financial statement separately, they are all interrelated. The changes in Adicet Bio's assets and liabilities, for example, are also reflected in the revenues and expenses on on Adicet Bio's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 86 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Adicet Stock Analysis
When running Adicet Bio's price analysis, check to measure Adicet Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adicet Bio is operating at the current time. Most of Adicet Bio's value examination focuses on studying past and present price action to predict the probability of Adicet Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adicet Bio's price. Additionally, you may evaluate how the addition of Adicet Bio to your portfolios can decrease your overall portfolio volatility.